If you have been reading about IRAP and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
DNA polymerase Any of a class of enzymes which synthesize DNA molecules from individual deoxyribonucleotides. DNA polymerases are essential for DNA replication and usually work in pairs to create identical copies of the two strands of an original double-stranded molecule. They build long chains of DNA by adding nucleotides one at a time to the 3'-end of a DNA strand, usually relying on the template provided by the complementary strand to copy the nucleotide sequence faithfully.
The frequency of error during the DNA replication process of gametogenesis, especially amplified in the rapid production of sperm cells, can promote more opportunities for de novo mutations to replicate unregulated by DNA repair machinery. This claim combines the observed effects of increased probability for mutation in rapid spermatogenesis with short periods of time between cellular divisions that limit the efficiency of repair machinery. Rates of de novo mutations that affect an organism during its development can also increase with certain environmental factors. For example, certain intensities of exposure to radioactive elements can inflict damage to an organism's genome, heightening rates of mutation. In humans, the appearance of skin cancer during one's lifetime is induced by overexposure to UV radiation that causes mutations in the cellular and skin genome.
Metrohm AG is an internationally active producer of precision instruments for chemical analysis, in particular ion analysis, based in Herisau, Switzerland. Metrohm is the leading manufacturer of titration devices and one of the two biggest manufacturers of ion chromatography systems. Besides, the product range includes systems for near-infrared and Raman spectroscopy, electrochemical measurements, and process analytics. These products are used in industries such as pharmaceuticals, food, chemicals, energy, and environmental analysis.
Sources: en.wikipedia.org
== Clinical significance == Activation of the ERK1/2 pathway by aberrant RAS/RAF signalling, DNA damage, and oxidative stress leads to cellular senescence. Low doses of DNA damage resulting from cancer therapy cause ERK1/2 to induce senescence, whereas higher doses of DNA damage fail to activate ERK1/2, and thus induce cell death by apoptosis.
=== Working with governors === As treasurer, Kennedy often clashed with governors and state legislators from both political parties, especially over spending and tax increases. He advocated for reducing state bureaucracy by cutting unnecessary state government jobs. In 2006, Kennedy criticized Governor Kathleen Blanco for including more than $9 million in spending he deemed "pork". He sent Blanco a six-page document of suggested cuts she could make as line-item vetoes. Kennedy said his list was "based upon the fact that many of the entities do not appear to be government entities, the lack of information about many of the items or entities, and that many of the items should have been considered through the entire process and/or included in other appropriate places in the budget to ensure proper public scrutiny, input and accountability." During his third term as treasurer, Kennedy devised a 24-point plan by which the state could save money. Governor Bobby Jindal said Kennedy could "streamline" his own department. Many of Kennedy's ideas were derived from the Louisiana Commission for Streamlining Government, on which he served in his official capacity as treasurer. Kennedy later accused Jindal's administration of check kiting, a controversial accounting practice whereby the governor took money from the 2014-2015 budget to cover debts from the 2013-2014 budget.
== Structure == While an Army unit, the Selous Scouts came under the operational control of Special Branch from its establishment in November 1973. This involved Special Branch controlling where the unit operated and how the intelligence it collected was used. Special Branch also had some influence over the Selous Scouts' training. In terms of Army hierarchy, the Selous Scouts reported directly to Walls. The unit was under orders from Special Branch to not pass any information directly to the Rhodesian Directorate of Military Intelligence, which contributed to very little of the intelligence it collected being provided to Army units. The Selous Scouts and other Rhodesian special forces continued to report directly to Walls for military purposes after he became the Commander of Combined Operations (COMOPS) in 1977. The Army headquarters provided administrative and logistical support. As the Selous Scouts increased in size and increasingly undertook offensive operations it became impossible for Special Branch to adequately oversee the unit. Each troop within the Selous Scouts comprised three sections, each usually with nine to twelve men. The size of sections varied, however, and could be as large as 30 men. Selous Scout teams usually included both black and white personnel, with the men forming close bonds. Until almost the end of the war, all of the officers in the Selous Scouts were white.
=== Replication cycle === Virus infections start when viral particles bind to host surface cellular receptors. Protein modelling experiments on the spike protein of the virus soon suggested that SARS‑CoV‑2 has sufficient affinity to the receptor angiotensin converting enzyme 2 (ACE2) on human cells to use them as a mechanism of cell entry. By 22 January 2020, a group in China working with the full virus genome and a group in the United States using reverse genetics methods independently and experimentally demonstrated that ACE2 could act as the receptor for SARS‑CoV‑2. Studies have shown that SARS‑CoV‑2 has a higher affinity to human ACE2 than the original SARS virus. SARS‑CoV‑2 may also use basigin to assist in cell entry. Initial spike protein priming by transmembrane protease, serine 2 (TMPRSS2) is essential for entry of SARS‑CoV‑2. The host protein neuropilin 1 (NRP1) may aid the virus in host cell entry using ACE2. After a SARS‑CoV‑2 virion attaches to a target cell, the cell's TMPRSS2 cuts open the spike protein of the virus, exposing a fusion peptide in the S2 subunit, and the host receptor ACE2. After fusion, an endosome forms around the virion, separating it from the rest of the host cell. The virion escapes when the pH of the endosome drops or when cathepsin, a host cysteine protease, cleaves it. The virion then releases RNA into the cell and forces the cell to produce and disseminate copies of the virus, which infect more cells. SARS‑CoV‑2 produces at least three virulence factors that promote shedding of new virions from host cells and inhibit immune response.
Sources: en.wikipedia.org
== Structure == The basement membrane was first described in skeletal muscle tissue in the 1800s. The beginnings of a molecular understanding only came about in the 1970s and 1980s. Epithelial cells are polarized. The surface of epithelial cells that face the lumen is the apical surface, and the surface facing the basement membrane is the basal surface. The basement membrane may be described as having two layers or laminae, an external basal lamina, facing the epithelium, and an internal basal lamina that faces the connective tissue. These two laminae are also known as the basal lamina and the reticular lamina. The cells in the internal basal membrane that are closest to the connective tissue show high rates of mitosis, needed to replace skin cell abrasions, and in the GI tract replacement of the cells exposed to digestive enzymes and gastric acid. In the skin the basement membrane is part of a more complex basement membrane zone. In the mucous membrane linings such as the gastric mucosa the basement membrane overlies loose connective tissue known as the lamina propria. The basement membrane is synthesized by cells on either side. One set of components are synthesized from the basal epithelial cells, and the other comes from the underlying connective tissue. Together the basement membrane contains glycoproteins – laminins, type IV collagen, and nidogen, and proteoglycans – perlecan, heparan sulfate proteoglycan, and agrin that blend together. Other components may include fibronectin and type XVIII collagen.
=== Laboratory synthesis === Heavy neutron irradiation of plutonium results in four major isotopes of einsteinium: 253Es (α-emitter; half-life 20.47 days, spontaneous fission half-life 7×105 years); 254mEs (β-emitter, half-life 39.3 hours), 254Es (α-emitter, half-life 276 days) and 255Es (β-emitter, half-life 39.8 days). An alternative route involves bombardment of uranium-238 with high-intensity nitrogen or oxygen ion beams. 247Es (half-life 4.55 min) was produced by irradiating 241Am with carbon or 238U with nitrogen ions. The latter reaction was first realized in 1967 in Dubna, Russia, and the involved scientists were awarded the Lenin Komsomol Prize. 248Es was produced by irradiating 249Cf with deuterium ions. It mainly β-decays to 248Cf with a half-life of 25±5 minutes, but also releases 6.87-MeV α-particles; the ratio of β's to α-particles is about 400.
== Overview of religious studies work as characterized by Klaus von Stosch == Translated from German into English by Friederike von Schwerin-High (professor of German studies at Pomona College since 2005; PhD from UMass Amherst in comparative literature; research interests: narrative theory, translation studies and eighteenth-century literature). Klaus von Stosch, a comparative theologian from Bonn who has held the Chair of Systematic Theology at the University of Bonn since the 2021/2022 winter semester, has been familiar with Kermani's religious studies work since its inception and classifies it as follows: Even though Kermani does not consider himself a theologian, his texts on Islam and religious studies clearly go beyond a purely descriptive approach. In many places, the texts are a plea for a new take on the Koran and on Islamic tradition, but also for a more comprehensive view of other religions. Emphasizing the mystical, experiential dimension of religions, his texts tend to approach religion on an aesthetic level. However, his writings do not only address the union of human beings with God, which is paramount tomysticism, and to the associated notions of love and happiness. He is also concerned with the glory and terror of God, in other words, with all aspects of God's inexpressible mystery. From a theological point of view, Kermani attaches importance to the unity of God and the unity of all being in a decidedly classical sense. Everything comes from the One and returns to it—like the breath of human beings.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.